Adrenergics Overview

  • Founded
  • 2015
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Adrenergics General Information

Description

Developer of novel therapeutics designed to treat dilated cardiomyopathy (DCM). The company's therapeutics focus on developing medicines that are expected to modulate disease progression leading to improved outcomes, enabling patients to overcome difficult-to-treat situations.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • San Diego, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Adrenergics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 05-Sep-2017 0000 Completed Out of Business
1. Early Stage VC (Series A) 15-Jun-2015 0000 0000 Completed Startup
To view Adrenergics’s complete valuation and funding history, request access »

Adrenergics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 000
To view Adrenergics’s complete cap table history, request access »